Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of “Different Diseases with the Same Treatment” Based on Network Pharmacology

Author:

Su Huihui1ORCID,Wu Guosong2ORCID,Zhan Lulu1ORCID,Xu Fei1ORCID,Qian Huiqin1ORCID,Li Yanling1ORCID,Zhu Ximei3ORCID

Affiliation:

1. College of Pharmacy, Sanquan College of Xinxiang Medical University, Xinxiang 453000, China

2. Department of Pharmacy, Baiyun Branch of Nanfang Hospital of Southern Medical University, Guangzhou 510599, China

3. Clinical Pharmacists, The Maternal and Child Health Care Hospital of HuaDu District (Huzhong Hospital), Guangzhou 510800, China

Abstract

The 31 main components of Lianhua Qingwen (LHQW) were obtained through a literature and database search; the components included glycyrrhizic acid, emodin, chlorogenic acid, isophoroside A, forsythia, menthol, luteolin, quercetin, and rutin. Sixty-eight common targets for the treatment of novel coronavirus pneumonia (NCP) and influenza virus pneumonia (IVP) were also obtained. A “component-target-disease” network was constructed with Cytoscape 3.2.1 software, and 20 key targets, such as cyclooxygenase2 (COX2), interleukin-6 (IL-6), mitogen-activated protein kinase14 (Mapk14), and tumor necrosis factor (TNF), were screened from the network. The David database was used to perform a Kyoto Encyclopedia of Genes and Genomes (KEGG) signal pathway enrichment analysis and gene ontology (GO) biological process enrichment. Results showed that the key targets of LHQW in the treatment of NCP and IVP mainly involved biological processes, such as immune system process intervention, cell proliferation, apoptosis and invasion, toxic metabolism, cytokine activity, and regulation of the synthesis process. KEGG enrichment analysis revealed that 115 signalling pathways were related to the treatment of LHQW. Amongst them, IL-17, T cell receptor, Th17 cell differentiation, TNF, toll-like receptor, MAPK, apoptosis, and seven other signalling pathways were closely related to the occurrence and development of NCP and IVP. Molecular docking showed that each component had different degrees of binding with six targets, namely, 3C-like protease (3CL), angiotensin-converting enzyme 2 (ACE2), COX2, hemagglutinin (HA), IL-6, and neuraminidase (NA). Rutin, isoforsythiaside A, hesperidin and isochlorogenic acid B were the best components for docking with the six core targets. The first five components with the best docking results were isoforsythiaside, hesperidin, isochlorogenic acid B, forsythin E, and quercetin. In conclusion, LHQW has many components, targets, and pathways. The findings of this work can provide an important theoretical basis for determining the mechanism of LHQW in treating NCP and IVP.

Funder

University-level application project of Xinxiang Medical University

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

Reference84 articles.

1. Clinical application and research progress of Lianhua Qingwen preparation;J. J. Zhu;Strait Pharmaceutical Journal,2019

2. Retrospective clinical study on novel coronavirus pneumonia treated with Lianhua Qingwen;K. T. Yao;Chinese Journal of Experimental Traditional Medical Formulae,2020

3. Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients

4. Novel coronavirus pneumonitis patients treated with Chinese herbal medicine Lianhua Qingwen: a multicenter retrospective study of 51 cases;D. Z. Cheng;Tianjin Journal of Traditional Chinese Medicine,2020

5. Novel coronavirus pneumonia suspected cases treated with Lianhua Qingwen Decoction: a clinical observation of 63 cases;R. B. Lv;Journal of Traditional Chinese Medicine,2020

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3